<DOC>
	<DOCNO>NCT03095209</DOCNO>
	<brief_summary>Patients observation study must plan treatment regimen concurrent CRT follow plan surgery , consider standard care disease . The total radiation dose 50.4 Gy daily fraction 1.8 Gy esophageal cancer 60 Gy daily fraction 2 Gy non-small cell lung cancer . The concurrent chemo regimen carboplatin-paclitaxel manage treat medical oncologist . Patients plan receive surgery approximately 6 9 week ( maximum 12 week post-CRT ) finish CRT surgical aspect determine treat surgical oncologist . Patients observation study donate blood sample within 4 week initiate CRT , within 1 week complete CRT , 1 month CRT , 1 month surgery ( 3 month CRT surgery do reason ) . They also request fill questionnaire ( EORTC QLQ-30 , EORTC QLQ-OES18 , Pain Scale attach ) prior CRT , weekly CRT , 1 month CRT , 1 month surgery ( 3 month CRT surgery do reason ) , 6 month CRT . Any patient incomplete treatment sample collect point discontinue . The specimen collection , handle process do Protocol Support Lab ( PSL ) Fox Chase Cancer Center direction Director , R. Katherine Alpaugh , PhD , follow procedure outline PSL lab manual . The patient observation study ask donate tissue specimen definitive surgery investigation .</brief_summary>
	<brief_title>Observation Study Patients With Non-Small Cell Lung Cancer Esophageal Cancer Treated With Chemo-Radiation Followed Surgery</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patient must pathologicallyconfirmed previously untreated : Nonsmall cell lung cancer , Stage IIIA ( T13 N2 M0 ) ; OR Localized esophageal cancer , ≥T2 , N+ , M0 accord American Joint Committee Cancer ( AJCC ) 7th edition staging . 2 . The planned treatment regimen must concurrent chemoradiation CarboplatinPaclitaxel follow surgery . 3 . Age &gt; 18 year . 4 . ECOG performance status 01 . 5 . Laboratory study must meet follow criterion ( labs drawn within 4 week prior registration ) : Absolute neutrophil count ( ANC ) ≥ 1,500 cells/mm3 Platelets ≥100,000 cells/mm3 Hemoglobin ≥ 8.0 g/dl ( Note : The use transfusion intervention achieve Hgb ≥ 8.0 g/dl acceptable ) Creatinine ≤2 X upper limit normal Bilirubin ≤ 1.5 X upper limit normal AST ≤ 3 X upper limit normal 6 . Men woman childbearing potential must willing exercise effective form birth control ( abstinence/contraception ) study 3 month therapy complete . 7 . Patients must able read write English comply questionnaire portion protocol . 8 . Subjects must sign write informed study consent HIPAA consent prior performance studyspecific procedures assessment must willing comply treatment follow . 1 . Patients previous radiotherapy thorax . 2 . Patients history ataxia telangiectasia document history radiation hypersensitivity . 3 . Patients history scleroderma active connective tissue disease . 9 Women childbearing potential must pregnant nonlactating . They require negative serum pregnancy test within 72 hour prior registration decline pregnancy test specific support reason sexually active use birth control ; postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ; woman status post oophorectomy hysterectomy consider nonchildbearing potential . 4 Patients uncontrolled intercurrent illness include , limited , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>